Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. ANSYS, Inc.

14.1% sales growth and 11.79% return on equity

ANSYS, Inc. develops and markets engineering simulation software and services worldwide.

ANSYS, Inc.’s sales growth this year is expected to be 6.8% and 12% for next year.

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 1.54B for the twelve trailing months.

ANSYS, Inc.’s sales growth for the next quarter is 14.1%. The company’s growth estimates for the ongoing quarter and the next is 13.4% and 31.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.79%.

Volatility

ANSYS, Inc.’s last day, last week, and last month’s average volatility was 2.64%, 0.60%, and 0.45%, respectively.

ANSYS, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.95%, 3.27%, and 2.41%, respectively.

ANSYS, Inc.’s Stock Yearly Top and Bottom Value

ANSYS, Inc.’s stock is valued at $374.66 at 16:22 EST, under its 52-week high of $375.78 and way above its 52-week low of $200.07.

ANSYS, Inc.’s Moving Average

ANSYS, Inc.’s worth is higher than its 50-day moving average of $347.05 and way higher than its 200-day moving average of $323.94.

2. Gilead Sciences

15.8% sales growth and 6.46% return on equity

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.

Gilead Sciences’s sales growth this year is anticipated to be 7.1% and a negative 0% for next year.

Year-on-year quarterly revenue growth grew by 17.4%, now sitting on 23.15B for the twelve trailing months.

News about Gilead Sciences today

According to today’s article on Bloomberg Quint, "The Supreme Court rebuffed a bid by Merck & Co.’s Idenix to revive a record verdict against Gilead Sciences Inc. in a dispute over a patent for a hepatitis C treatment."

Gilead Sciences’s sales growth for the next quarter is 15.8%. The company’s growth estimates for the present quarter and the next is 46.9% and 10.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.46%.

Volatility

Gilead Sciences’s last day, last week, and last month’s average volatility was 1.49%, 0.09%, and 0.31%, respectively.

Gilead Sciences’s last day, last week, and last month’s high and low average amplitude percentage was 2.37%, 2.29%, and 2.03%, respectively.

Gilead Sciences’s Stock Yearly Top and Bottom Value

Gilead Sciences’s stock is valued at $67.08 at 16:22 EST, way below its 52-week high of $85.97 and way above its 52-week low of $56.56.

Gilead Sciences’s Moving Average

Gilead Sciences’s worth is way above its 50-day moving average of $60.12 and higher than its 200-day moving average of $64.46.

3. Qorvo, Inc.

19.2% sales growth and 10.28% return on equity

Qorvo, Inc. develops and commercializes technologies and products for wireless and wired connectivity worldwide.

Qorvo, Inc.’s sales growth this year is expected to be 18.5% and 9.9% for next year.

Year-on-year quarterly revenue growth grew by 31.4%, now sitting on 3.5B for the twelve trailing months.

Qorvo, Inc.’s sales growth is a negative 0% for the present quarter and 19.2% for the next. The company’s growth estimates for the current quarter and the next is 43% and 26.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.28%.

Volatility

Qorvo, Inc.’s last day, last week, and last month’s average volatility was 1.87%, 2.12%, and 0.63%, respectively.

Qorvo, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.77%, 3.54%, and 2.78%, respectively.

Qorvo, Inc.’s Stock Yearly Top and Bottom Value

Qorvo, Inc.’s stock is valued at $182.76 at 16:22 EST, below its 52-week high of $184.47 and way higher than its 52-week low of $67.54.

Qorvo, Inc.’s Moving Average

Qorvo, Inc.’s value is way higher than its 50-day moving average of $162.71 and way above its 200-day moving average of $136.70.

4. Flushing Financial Corporation

29.8% sales growth and 7.64% return on equity

Flushing Financial Corporation operates as the bank holding company for Flushing Bank that provides banking products and services primarily to consumers, businesses, and governmental units.

Flushing Financial Corporation’s sales growth this year is expected to be 19.8% and 13.4% for next year.

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 178.96M for the twelve trailing months.

Flushing Financial Corporation’s sales growth for the next quarter is 29.8%. The company’s growth estimates for the present quarter and the next is 5% and 121.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.64%.

Volatility

Flushing Financial Corporation’s last day, last week, and last month’s average volatility was a negative 1.04%, a positive 2.05%, and a positive 0.69%, respectively.

Flushing Financial Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 3.06%, 4.33%, and 3.53%, respectively.

Flushing Financial Corporation’s Stock Yearly Top and Bottom Value

Flushing Financial Corporation’s stock is valued at $18.33 at 16:22 EST, way under its 52-week high of $21.39 and way above its 52-week low of $8.86.

Flushing Financial Corporation’s Moving Average

Flushing Financial Corporation’s value is way higher than its 50-day moving average of $16.07 and way higher than its 200-day moving average of $12.72.

LEAVE A REPLY

Please enter your comment!
Please enter your name here